Basel, Switzerland, and Napa, California (USA), 18 November 2010 – Lonza and California Peptide Research, Inc. (CPRI) have entered into a strategic collaboration to more effectively serve customers requesting peptide manufacturing and development services.
CPRI’s high-quality small-scale services complement Lonza's extensive capabilities in custom cGMP peptide manufacturing and development. With proximity to a core customer base in the North American pharmaceutical market, CPRI adds geographic diversity to Lonza's existing facilities in Braine-l'Alleud (Belgium), Visp (Switzerland), Nansha (China), and Kouřim (Czech Republic). CPRI’s offering includes milligram- to multi-gram-scale custom synthesis and a wide variety of catalogue products, as well as consulting services and technical support.
The alliance will provide customers a more complete peptide offering – from research through commercial supply – and enable a seamless transition of custom peptide projects between CPRI’s small-scale facility and Lonza’s cGMP facilities. Joint customers will benefit from aligned interfaces and more efficient technology transfer, thereby saving time and costs.
CPRI was identified as a competent innovator and qualified as a Lonza-trusted partner following a diligent selection and auditing process.
